Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by a Donor Stem Cell Transplant in Treating Patients With Immunodeficiency or Other Nonmalignant Inherited Disorders

Key facts

Sponsor

Fred Hutchinson Cancer Center

Principal Investigator

Lauri Burroughs

Fred Hutch/University of Washington Cancer Consortium

Intervention

Alemtuzumab(biological)

Enrollment

29 enrolled

Eligibility

54 years · All sexes

Timeline

2006

Study locations (6)

• Children's Hospital and Research Center at Oakland, Oakland, California, United States
• Cleveland Clinic Foundation, Cleveland, Ohio, United States
• Oregon Health and Science University, Portland, Oregon, United States
• Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
• Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
• Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States

Collaborators

National Cancer Institute (NCI) · National Heart, Lung, and Blood Institute (NHLBI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for OBSOLETE: Other complex syndrome of primary immunodeficiency

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT06332196
  Immunodeficiency and Cancer: Identification of Congenital Immune System Defects Underlying Paediatric Lymphomas
  Meyer Children's Hospital IRCCS
• RECRUITINGNCT04990908
  Systematic Screening for Primary Immunodeficiencies in Patients Admitted for Severe Infection in Pediatric Intensive Care Unit
  University Hospital, Montpellier
• RECRUITINGPHASE2NCT05421325
  Efficacy of QBKPN Site-Specific Immunomodulator in Improving Innate Immune Function & Reducing Respiratory Tract Infection in Older Adults
  Qu Biologics Inc.
• RECRUITINGNCT04784364
  Biologics And Clinical Immunology Cohort at Sinai
  Icahn School of Medicine at Mount Sinai
• ACTIVE NOT RECRUITINGPHASE3NCT04565015
  Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency
  GC Biopharma Corp
• RECRUITINGNCT04459689
  COVID-19 in PID Survey
  Imagine Institute
• RECRUITINGPHASE2NCT04232085
  Regenerative Medicine to Restore Hematopoiesis and Immune Function in Immunodeficiencies and Inherited Bone Marrow Failures
  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• ACTIVE NOT RECRUITINGPHASE2NCT01821781
  Immune Disorder HSCT Protocol
  Washington University School of Medicine

See all trials for OBSOLETE: Other complex syndrome of primary immunodeficiency →